Navigation Links
MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
Date:12/11/2007

Three Alternative Five-day Dosing Schedules Appear Similar to Seven-Day in Achieving Red Blood Cell Transfusion Independence, Hematologic Improvement

in All MDS Patients Tested Data Presented at the 49th American Society of Hematology (ASH) Meeting

ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced interim data from a Phase 2 clinical trial evaluating three alternative five-day dosing schedules for Vidaza(R) (azacitidine for injection) that demonstrated safety and response profiles which are consistent with those achieved with the FDA-approved seven-day regimen, as reflected in rates of hematologic improvement (HI) and red blood cell (RBC) transfusion independence. These responses were observed in a broad range of MDS patients, including FAB low-risk patients. These data were presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta.

"The data from this study suggest that a five-day schedule is as effective as the currently approved seven-day schedule at achieving RBC transfusion independence and hematologic improvement in MDS patients," said Dr. Andrew R. Allen, executive vice president and chief medical officer of Pharmion. "A dosing schedule that circumvents the need for weekend dosing would provide a meaningful benefit in terms of convenience to these patients and clinicians."

Roger M. Lyons, MD, FACP, principal investigator of the study at Cancer Care Centers of South Texas and U.S. Oncology Research San Antonio delivered an oral presentation titled "Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza) in Patients with Myelodysplastic Sy
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  The American Diabetes Association is recommending a ... with diabetes and that all people with diabetes ... in keeping with recent changes to guidelines for ... of Cardiology (ACC) and American Heart Association (AHA). ... changes to the Association,s annual revised Standards of ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... , OMAHA, Neb., Dec. 4 Amber ... Accreditation Commission for Health Care, Inc. (ACHC) for specialized ... provided comprehensive pharmacy care programs and services to meet ... one of the leading providers of services to transplant ...
... , ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE ... against biological and chemical threats, announced today the presentation of ... its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is ... up to and including 55 degrees C. The data ...
Cached Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... The short film “Color of Honor” by ... of a true 9/11 hero, Welles Remy Crowther. It has ... 24 hours of Nuremberg International Short Film Festival and the ... Actress, screenwriter and director Luciana Lagana plays the mother ... her husband, Gregory Graham - Graham plays a ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... and Eliza Hall,Institute of Medical Research (WEHI) announced ... a leading biotechnology company,based in South San Francisco ... to discover new anti-cancer drugs., "This exciting ... field may increase the chance of translating basic ...
... growing away-from-home ... washroom ... announced it has signed a definitive agreement to acquire,Technical Concepts ... hygiene systems for several high-growth,segments of the away-from-home ("AFH") washroom ...
... High-Performance ... Academia, SOUTHPOINTE, Pa., Feb. 27 ANSYS, ... simulation software and technologies,designed to optimize product development ... and Technology Information (KISTI), one of,the world,s largest ...
... To Enhance Body, Mind & Spirit, VAIL, ... approach to healthcare, Next Step(R) Institute of Integrative,Medicine, ... Colorado, has recently announced its 2008 series of ... Next Step(R) Institute Wellness Weeks are six-night, five-day ...
... popular among,30-somethings who don,t want to look a ... somethings who,d like to look 40 again, StriVectin(R)-HS,Hydro-Thermal ... as the only,"great" beauty serum for older complexions ... just published "beauty serum" ranking., (Photo: ...
... Two emergency care training,organizations acquired by a single ... created parent company at the helm -- and aggressive ... The Riverside Company, which purchased the American Safety & ... over a year,ago, recently created parent company, the Health ...
Cached Medicine News:Health News:Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs 2Health News:Newell Rubbermaid to Grow Commercial Products Platform with Agreement to Acquire Technical Concepts 2Health News:Newell Rubbermaid to Grow Commercial Products Platform with Agreement to Acquire Technical Concepts 3Health News:Newell Rubbermaid to Grow Commercial Products Platform with Agreement to Acquire Technical Concepts 4Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 2Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 3Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 4Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 2Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 3Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 4Health News:America's StriVectin the Only 'Great' Serum for Mature, Aging Complexions, Says Leading British Newspaper 2Health News:New Health & Safety Institute Creates Extensive, Centralized Resource for Emergency Care Training 2
Guaranteed leak-proof , Teflon coating is impervious to corrosive materials , Shock-resistant , NBS tolerances of accuracy , Thermometers are 225 mm long with an immersion length of 35 mm ...
... laboratory system for pH and temperature measurements. ... when used with a temperature probe (ATC) ... easy one and two-point calibration with Auto-Find ... 1.68, 4.00, 7.00, 10.01 and 12.45) and ...
... The DTX Series Multimode Detectors provide ... variety of application and automation needs. ... absorbance measurements on the same instrument, ... standalone instruments or can be integrated ...
... Expert: Detection of PCR, cDNA and Oligonucleotides ... microplate reader for a variety applications that are ... is suitable to handle assays in Microplate ... PCR tubes Cuvettes Independent whether ...
Medicine Products: